Skip to main navigation Skip to search Skip to main content

Final product composition after ex-vivo T-cell reduction: Miltenyi CliniMACS versus Baxter Isolex 300I in a large cohort of allogeneic trans-plant patients

  • J. Tonon
  • , G. Koehne
  • , N.H. Collins
  • , M. Malloy
  • , X. Chen
  • , S. Bleau
  • , M. Pessin
  • , K. Smith
  • , P. Maslak
  • , S. Devlin
  • , S.A. Giralt
  • , R.J. O'Reilly
  • , A.A. Jakubowski
  • , R.C. Meagher

Research output: Contribution to conferencePresentation

Original languageAmerican English
DOIs
StatePublished - Apr 1 2013
EventCytotherapy -
Duration: Jan 4 2014 → …

Conference

ConferenceCytotherapy
Period1/4/14 → …

Disciplines

  • Biology
  • Immunology and Infectious Disease

Cite this